Safety and efficacy assessment of Synskin Acnes 2 cream” and Acnes 3 cream” for treatment of acne

Phase 2

• Conditions: L70.0; Acne vulgaris.; Acne vulgaris

• Registration Number: IRCT20190210042676N14
• Lead Sponsor: Iran Avandfar Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Male or female aged 16-40 years
Mild to moderate inflammatory or non-inflammatory acne lesions (grade 1 to 3 according to the table) on face

Exclusion Criteria

People with allergies to formulation ingredients
Nodular or cystic lesions that represent a severe type of acne vulgaris

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the improvement of acne severity index by a physician. Timepoint: Before intervention, 2, 6 and 10 weeks after the start of use. Method of measurement: 0=normal skin, 2=skin is almost clear, 3=some non-inflammatory lesions are present, 4=non-inflammatory lesions are predominant, with multiple inflammatory lesions. 5=highly inflammatory lesions predominate.

Secondary Outcome Measures

Name	Time	Method
Trans Epidermal Water Loss. Timepoint: Before intervention, 2, 6 and 10 weeks after the start of use. Method of measurement: Tewameter.;Skin sebum. Timepoint: Before intervention, 2, 6 and 10 weeks after the start of use. Method of measurement: Sebumeter.